{"filing":{"accession_number":"0001193125-26-277563","cik":"0001650648","ticker":"FDMT","company_name":"4D Molecular Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"fdmt-20260617.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526277563/fdmt-20260617.htm"},"events":[{"id":12791,"run_id":11350,"accession_number":"0001193125-26-277563","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from the Company's 2026 Annual Meeting of Stockholders held on June 17, 2026. The filing reports voting outcomes for three proposals: election of Class III directors (Proposal 1), ratification of PricewaterhouseCoopers LLP as independent auditor (Proposal 2), and advisory approval of named executive officer compensation (Proposal 3), with detailed vote tallies for each. This is a standard Item 5.07 disclosure and is material as it reflects stockholder approval of governance and compensation matters.","company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9743,"accession_number":"0001193125-26-277563","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from the Company's 2026 Annual Meeting of Stockholders held on June 17, 2026. The filing reports voting outcomes for three proposals: election of Class III directors (Proposal 1), ratification of PricewaterhouseCoopers LLP as independent auditor (Proposal 2), and advisory approval of named executive officer compensation (Proposal 3), with detailed vote tallies for each. This is a standard Item 5.07 disclosure and is material as it reflects stockholder approval of governance and compensation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:52:42.906911+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9743,"accession_number":"0001193125-26-277563","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from the Company's 2026 Annual Meeting of Stockholders held on June 17, 2026. The filing reports voting outcomes for three proposals: election of Class III directors (Proposal 1), ratification of PricewaterhouseCoopers LLP as independent auditor (Proposal 2), and advisory approval of named executive officer compensation (Proposal 3), with detailed vote tallies for each. This is a standard Item 5.07 disclosure and is material as it reflects stockholder approval of governance and compensation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:52:42.906911+00:00","company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","filing_date":"2026-06-22"}]}